BofA raised the firm’s price target on Amgen (AMGN) to $275 from $256 and keeps an Underperform rating on the shares. Q4 results were slightly ...

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The ...

Asian shares are trading mostly higher after a Wall Street rally that followed profit reports from major companies ...

The post contains 50 new customer stories, which appear at the beginning of each section of customer lists. The post will be ...